Clinical Trials Using Oxidative Phosphorylation Inhibitor IACS-010759

Clinical trials are research studies that involve people. The clinical trials on this list are studying Oxidative Phosphorylation Inhibitor IACS-010759. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • IACS-010759 in Treating Patients with Relapsed or Refractory Lymphoma or Solid Tumors That Are Advanced, Metastatic, or Unresectable

    This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or solid tumors that have spread to other places in the body (advanced / metastatic) or cannot be removed by surgery (unresectable). IACS-010759 may stop the growth of cancer or tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas